Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cervical neoplasia is the abnormal growth of cells on the surface of the cervix that could potentially lead to cervical cancer. Our work translates into developing and testing novel therapeutics aiming to eradicate persistent human papillomaviruses (HPV) infections in women with established pre-cancerous lesions in clinical trials. This has recently led to the first in-human trial of the world’s broadest HPV vaccine – and is a major milestone in the fight against HPV associated cancers.

What's new

First woman in UK receives dose of therapeutic HPV vaccine

NDWRH and Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of vaccines for the treatment and prevention of infectious diseases and cancer, see the first woman in the UK receive the first dose of a novel therapeutic HPV vaccine for the HPV001 clinical trial in Oxford.

Latest publications

Related research themes